Profit profile helps Lilly shares rebound from Alzheimer's setback

Profit profile helps Lilly shares rebound from Alzheimer's setback


Shares of Eli Lilly & Co have staged a dramatic rebound following massive disappointment for its experimental Alzheimer's medicine late last year, outperforming rivals as investors warm to the drugmaker's profit outlook. Investors are counting on Lilly's stable of new products for conditions such as diabetes and psoriasis to propel its earnings above those of industry peers over the next several years.



from Biotech News